US 12,129,247 B2
Administration regime for nitrocatechols
Patricio Manuel Vieira Araujo Soares Da Silva, São Mamede do Coronado (PT); Teresa Lucia Silva Pereira Nunes, São Mamede do Coronado (PT); Lyndon Christopher Wright, São Mamede do Coronado (PT); Pedro Nuno Leal Palma, São Mamede do Coronado (PT); and David Alexander Learmonth, São Mamede do Coronado (PT)
Assigned to BIAL-PORTELA & CA, S.A., S. Mamede Do Coronado (PT)
Filed by BIAL-PORTELA & CA, S.A., São Mamede do Coronado (PT)
Filed on Aug. 28, 2018, as Appl. No. 16/114,430.
Application 16/114,430 is a division of application No. 13/963,621, filed on Aug. 9, 2013, granted, now 10,065,944.
Application 13/963,621 is a continuation of application No. 13/583,375, abandoned, previously published as PCT/GB2011/052056, filed on Oct. 21, 2011.
Claims priority of provisional application 61/441,988, filed on Feb. 11, 2011.
Prior Publication US 2019/0144436 A1, May 16, 2019
Int. Cl. A61K 31/165 (2006.01); A61K 31/198 (2006.01); A61K 31/4439 (2006.01); A61K 45/06 (2006.01); C07D 413/12 (2006.01)
CPC C07D 413/12 (2013.01) [A61K 31/165 (2013.01); A61K 31/198 (2013.01); A61K 31/4439 (2013.01); A61K 45/06 (2013.01)] 17 Claims
 
1. A method of treating Parkinson's disease, comprising orally administering to a human patient suffering from said disease, without food and/or between intakes of food, a therapeutically effective amount of compound 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol or a pharmaceutically acceptable salt thereof, wherein the compound is administered in combination with a therapeutically effective amount of levodopa.